Correlation Between Neurobo Pharmaceuticals and Plus Therapeutics

Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Plus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Plus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurobo Pharmaceuticals and Plus Therapeutics, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Plus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Plus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Plus Therapeutics.

Diversification Opportunities for Neurobo Pharmaceuticals and Plus Therapeutics

0.59

Correlation Coefficient

Neurobo Pharmaceuticals  Plus Therapeutics

Very weak diversification

The 3 months correlation between Neurobo and Plus is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Plus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Plus Therapeutics and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Plus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Plus Therapeutics has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Plus Therapeutics go up and down completely randomly.

Pair Corralation between Neurobo Pharmaceuticals and Plus Therapeutics

Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to under-perform the Plus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Neurobo Pharmaceuticals is 1.24 times less risky than Plus Therapeutics. The stock trades about -0.15 of its potential returns per unit of risk. The Plus Therapeutics is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  148.00  in Plus Therapeutics on September 13, 2024 and sell it today you would lose (13.00) from holding Plus Therapeutics or give up 8.78% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Neurobo Pharmaceuticals  vs.  Plus Therapeutics

Neurobo Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Plus Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Plus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Plus Therapeutics is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Neurobo Pharmaceuticals and Plus Therapeutics

The main advantage of trading using opposite Neurobo Pharmaceuticals and Plus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Plus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Plus Therapeutics will offset losses from the drop in Plus Therapeutics' long position.

The idea behind Neurobo Pharmaceuticals and Plus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.